Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Latvija - latviešu - Zāļu valsts aģentūra

orifarm healthcare a/s, denmark - chlorhexidini dihydrochloridum, lidocaini hydrochloridum - presēta sūkājamā tablete - 5 mg/1 mg

Latvija - latviešu - Zāļu valsts aģentūra

orifarm healthcare a/s, denmark - chlorhexidini dihydrochloridum, lidocaini hydrochloridum - presēta sūkājamā tablete - 5 mg/1 mg

Latvija - latviešu - Zāļu valsts aģentūra

orifarm healthcare a/s, denmark - chlorhexidini dihydrochloridum, lidocaini hydrochloridum - presēta sūkājamā tablete - 5 mg/1 mg

Latvija - latviešu - Zāļu valsts aģentūra

orifarm healthcare a/s, denmark - chlorhexidini dihydrochloridum, lidocaini hydrochloridum - presēta sūkājamā tablete - 5 mg/1 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - perindoprila terc-butilamīns - mutē disperģējamās tabletes - 4 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - perindoprila terc-butilamīns - mutē disperģējamās tabletes - 8 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - perindoprila terc-butilamīns - tablete - 8 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - perindoprila terc-butilamīns - tablete - 4 mg